FBXO30

Across TCGA pan-cancer cohorts, FBXO30 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO30 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher FBXO30 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO30 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where FBXO30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.569	0.774	.022	6	view →
HNSC	DFS	Quartile	III,IV	0.891	0.632	.026	6	view →
CCRCC	DFS	Quartile	All	0.500	0.979	.024	5	view →
PDAC	DFS	Median	II,III,IV	0.443	0.313	.039	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.886	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO30–GBM (DFS)

Open the GBM breakdown →